drugset / Trial / NCT00712270

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

NCT00712270

Phase 4 Terminated 21 enrolled Kettering Health Network
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs. This could help doctors prescribe the medication that will work best for each individual.

Timeline

Start
2005-04
Primary completion
2008-12
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 15 mg Oral
Comparator Risperidone Other / unclassified 2 mg Oral

Indications